tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

Nuvilex, Inc. COO Interview with Dr. Gerald Crabtree

Nuvilex, Inc. COO Interview with Dr. Gerald Crabtree

Nuvilex Inc.’s, (OTCQB: NVLX) Chief Operating Officer, Dr. Gerald Crabtree sat down for an interview with Stock Market Media Group, a research and content development investor relations firm.  In the interview, Dr. Crabtree covered a number of topics including the Nuvilex’s restructuring, its recent acquisition of a live-cell encapsulation-based technology, the company’s future pancreatic cancer clinical trials and the on-going relationship with SG Austria.   

The interview can be heard at www.stockmarketmediagroup.com/media.

As part of Stock Market Media Group’s CEO interview series, Dr. Crabtree discusses why it was necessary for the company to restructure its operations in order to solely focus on its work as a biotech firm.  He lays out the importance of the company’s recent acquisition of exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment the company will use in future clinical trials.  While discussing the technology, Dr. Crabtree explains why this technology works better than other cell encapsulation treatments.

Dr. Crabtree breaks down the current pancreatic cancer drug market, and outlines Nuvilex’s potential future success in it by taking a look into the numbers its technology has produced.  He answered a number of questions surrounding the company’s future clinical trials for the treatment of advanced, inoperable pancreatic cancer; including, responses to the steps already underway, future study sites, the protocol for the trials and SG Austria’s role in those upcoming trials. 

Dr. Crabtree has spent over 40 years working in the field of oncology.  He played a significant role in helping Bristol-Myers Squibb bring the widely popular cancer drug Taxol® to market.  Nuvilex’s COO is very familiar with the process of taking a drug/treatment through clinical trials, working with the Food and Drug Administration (FDA) and getting that drug to market.  Stock Market Media Group feels this interview will show Dr. Crabtree’s experience, knowledge and confidence with Nuvilex’s plans to engage in future clinical trials.

The interview can be heard at www.stockmarketmediagroup.com/media.